BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31178392)

  • 1. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.
    Panch SR; Srivastava SK; Elavia N; McManus A; Liu S; Jin P; Highfill SL; Li X; Dagur P; Kochenderfer JN; Fry TJ; Mackall CL; Lee D; Shah NN; Stroncek DF
    Mol Ther; 2019 Jul; 27(7):1275-1285. PubMed ID: 31178392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cryopreservation on chimeric antigen receptor T cell functions.
    Xu H; Cao W; Huang L; Xiao M; Cao Y; Zhao L; Wang N; Zhou J
    Cryobiology; 2018 Aug; 83():40-47. PubMed ID: 29908946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
    Tyagarajan S; Schmitt D; Acker C; Rutjens E
    Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
    Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.
    Su T; Ying Z; Lu XA; He T; Song Y; Wang X; Ping L; Xie Y; Tu M; Liu G; Qi F; Ding Y; Jing H; Zhu J
    Cryobiology; 2020 Oct; 96():106-113. PubMed ID: 32721392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.
    Künkele A; Brown C; Beebe A; Mgebroff S; Johnson AJ; Taraseviciute A; Rolczynski LS; Chang CA; Finney OC; Park JR; Jensen MC
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):223-232. PubMed ID: 30315942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
    Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
    J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
    Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
    Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
    J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a New Cryopreservation Solution for Chimeric Antigen Receptor T Cells.
    Tang Q; Gu L; Zhou B; Shi J; Wu H; Zhu H; Xu Y; Zhang T
    Biopreserv Biobank; 2022 Dec; 20(6):567-574. PubMed ID: 35294840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
    Stock S; Schmitt M; Sellner L
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics.
    Elavia N; Panch SR; McManus A; Bikkani T; Szymanski J; Highfill SL; Jin P; Brudno J; Kochenderfer J; Stroncek DF
    Transfusion; 2019 May; 59(5):1755-1764. PubMed ID: 30973976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
    Carbonell D; Monsalvo S; Catalá E; Pérez-Corral A; Villegas C; Falero C; Ruano G; Martinez M; Kwon M; Muñoz-Martínez C; Díez-Martín JL; Gayoso J; Anguita J
    Blood Transfus; 2024 May; 22(3):239-245. PubMed ID: 38063787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manufacturing chimeric antigen receptor T cells: issues and challenges.
    Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
    Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.